Phase 2 Gene Therapy Trial of Locally Advanced Pancreatic Adenocarcinoma Using Intratumoral Injection of CYL-02 in Combination With Gemcitabine
Latest Information Update: 03 Apr 2023
At a glance
- Drugs CYL 02 (Primary) ; Gemcitabine (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms THERGAP-02
- 29 Mar 2023 Status changed from active, no longer recruiting to completed.
- 27 Oct 2021 Planned End Date changed from 1 Nov 2021 to 1 Dec 2022.
- 27 Oct 2021 Planned primary completion date changed from 1 Nov 2020 to 1 Dec 2022.